Phenytoin sodiumSodium channel stabilizer CAS# 630-93-3 |
- Metformin HCl
Catalog No.:BCC4799
CAS No.:1115-70-4
- Lenalidomide (CC-5013)
Catalog No.:BCC2245
CAS No.:191732-72-6
- Gliclazide
Catalog No.:BCC5002
CAS No.:21187-98-4
- Geniposide
Catalog No.:BCN5104
CAS No.:24512-63-8
- MEK inhibitor
Catalog No.:BCC1738
CAS No.:334951-92-7
- Imeglimin hydrochloride
Catalog No.:BCC4085
CAS No.:775351-61-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 630-93-3 | SDF | Download SDF |
PubChem ID | 657302 | Appearance | Powder |
Formula | C15H11N2NaO2 | M.Wt | 274.25 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | 5,5-Diphenylhydantoin sodium salt | ||
Solubility | DMSO : 50 mg/mL (182.32 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | sodium;5,5-diphenylimidazolidin-3-ide-2,4-dione | ||
SMILES | C1=CC=C(C=C1)C2(C(=O)[N-]C(=O)N2)C3=CC=CC=C3.[Na+] | ||
Standard InChIKey | FJPYVLNWWICYDW-UHFFFAOYSA-M | ||
Standard InChI | InChI=1S/C15H12N2O2.Na/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12;/h1-10H,(H2,16,17,18,19);/q;+1/p-1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Phenytoin sodium is an inactive voltage-gated sodium channel stabilizer.
Target: Sodium Channel
Phenytoin sodium is an antiepileptic drug. It is useful to treat partial seizures and generalized tonic-clonic seizures but not primary generalized seizures such as absence seizures or myoclonic seizures. Phenytoin is believed to protect against seizures by causing voltage-dependent block of voltage-gated sodium channels [1]. Phenytoin has low affinity for resting sodium channels at hyperpolarized membrane potentials [2]. When neurons are depolarized and the channels transition into the open and inactivated states, greater binding and block occur. The inhibitory potency is strongly use dependent, so that block accumulates with prolonged or repetitive activation, such as occurs during a seizure discharge. The blocking of sodium channels by phenytoin is of slow onset. The time course of fast sodium currents is therefore not altered in the presence of the drug and action potentials evoked by synaptic depolarizations of ordinary duration are not blocked. Thus phenytoin is able to selectively inhibit pathological hyperexcitability in epilepsy without unduly impairing ongoing activity. Phenytoin also blocks persistent sodium current and this may be of particular importance in seizure control. Phenytoin is a class 1b antiarrhythmic [3]. References: |
Phenytoin sodium Dilution Calculator
Phenytoin sodium Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.6463 mL | 18.2315 mL | 36.4631 mL | 72.9262 mL | 91.1577 mL |
5 mM | 0.7293 mL | 3.6463 mL | 7.2926 mL | 14.5852 mL | 18.2315 mL |
10 mM | 0.3646 mL | 1.8232 mL | 3.6463 mL | 7.2926 mL | 9.1158 mL |
50 mM | 0.0729 mL | 0.3646 mL | 0.7293 mL | 1.4585 mL | 1.8232 mL |
100 mM | 0.0365 mL | 0.1823 mL | 0.3646 mL | 0.7293 mL | 0.9116 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Phenytoin is an inactive voltage-gated sodium channel stabilizer.Phenytoin is an antiepileptic drug. It is useful to treat partial seizures and generalized tonic-clonic seizures but not primary generalized seizures such as absence seizures or myoclonic se
- Ouabain
Catalog No.:BCC5069
CAS No.:630-60-4
- Nonacosane
Catalog No.:BCC9102
CAS No.:630-03-5
- Phenoxybenzamine HCl
Catalog No.:BCC4334
CAS No.:63-92-3
- L-Phenylalanine
Catalog No.:BCN3818
CAS No.:63-91-2
- Sulfanilamide
Catalog No.:BCC4858
CAS No.:63-74-1
- H-Met-OH
Catalog No.:BCC2993
CAS No.:63-68-3
- Primaquine Diphosphate
Catalog No.:BCC4706
CAS No.:63-45-6
- Androstenedione
Catalog No.:BCC8296
CAS No.:63-05-8
- Staurosporine
Catalog No.:BCC3612
CAS No.:62996-74-1
- 6-Aminoquinoxaline
Catalog No.:BCC8767
CAS No.:6298-37-9
- XL335
Catalog No.:BCC4501
CAS No.:629664-81-9
- Boc-Tle-OH
Catalog No.:BCC3343
CAS No.:62965-35-9
- Corynoxeine
Catalog No.:BCN5002
CAS No.:630-94-4
- Neoprzewaquinone A
Catalog No.:BCN4169
CAS No.:630057-39-5
- MRS 2500 tetraammonium salt
Catalog No.:BCC5881
CAS No.:630103-23-0
- PD 168077 maleate
Catalog No.:BCC6919
CAS No.:630117-19-0
- AST 487
Catalog No.:BCC1373
CAS No.:630124-46-8
- Androstenone hydrazone
Catalog No.:BCC8830
CAS No.:63015-10-1
- Crenulatin
Catalog No.:BCN7791
CAS No.:63026-02-8
- Hexacosyl (E)-ferulate
Catalog No.:BCN4170
CAS No.:63034-29-7
- Senkyunolide
Catalog No.:BCN8154
CAS No.:63038-10-8
- H-Tle-OMe.HCl
Catalog No.:BCC2658
CAS No.:63038-27-7
- Estradiol-3-benzoate-17-butyrate
Catalog No.:BCC8963
CAS No.:63042-18-2
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
Drug release, cell adhesion and wound healing evaluations of electrospun carboxymethyl chitosan/polyethylene oxide nanofibres containing phenytoin sodium and vitamin C.[Pubmed:26224348]
IET Nanobiotechnol. 2015 Aug;9(4):191-200.
In this work, N, O-carboxymethyl chitosan (CMCS) samples from virgin chitosan (CS) were synthesised and CMCS/polyethylene oxide (PEO) (50/50) blend nanofibrous samples were successfully electrospun from their aqueous solution. The electrospinning conditions to achieve smooth and fine diameter nanofibrous mats were optimised via D-optimal design approach. Afterwards, vitamin C and Phenytoin sodium (PHT-Na) were added to these samples for producing wound dressing materials. H-nuclear magnetic resonance, scanning electron microscopy and Fourier transform infrared tests for the evaluation of functionalised CS, morphology and biodegradability studies of CMCS/PEO blend nanofibrous samples were applied. The kinetic and drug release mechanism for vitamin C and PHT-Na drug-loaded electrospun samples were also investigated by UV-vis spectrophotometer and high performance liquid chromatography, respectively. The results showed an approximately similar drug release rate of the two drugs and followed Higuchi's kinetic model. The stem cells viability and their adhesion on the surface of the samples containing PHT-Na and vitamin C were carried out using MTT assay and the best cells' biocompatibility was obtained using both drugs into the CMCS/PEO nanofibrous samples. Moreover, the in vivo animal wound model results revealed that the electrospun samples containing vitamin C and PHT-Na (1%) had a remarkable efficiency in the wounds' closure and their healing process compared with vitamin C/PHT-Na (50/50) ointment. Finally, the histology observations showed that the wound treated with optimised electrospun samples containing two drugs enabled regeneration of epidermis layers due to collagen fibres accumulation followed by granulating tissues formation without necrosis.
The antiepileptic medications carbamazepine and phenytoin inhibit native sodium currents in murine osteoblasts.[Pubmed:27440235]
Epilepsia. 2016 Sep;57(9):1398-405.
OBJECTIVE: Fracture risk is a serious comorbidity in epilepsy and may relate to the use of antiepileptic drugs (AEDs). Many AEDs inhibit ion channel function, and the expression of these channels in osteoblasts raises the question of whether altered bone signaling increases bone fragility. We aimed to confirm the expression of voltage-gated sodium (NaV ) channels in mouse osteoblasts, and to investigate the action of carbamazepine and phenytoin on NaV channels. METHODS: Immunocytochemistry was performed on primary calvarial osteoblasts extracted from neonatal C57BL/6J mice and additional RNA sequencing (RNASeq) was included to confirm expression of NaV . Whole-cell patch-clamp recordings were made to identify the native currents expressed and to assess the actions of carbamazepine (50 mum) or phenytoin (50 mum). RESULTS: NaV expression was demonstrated with immunocytochemistry, RNA sequencing, and functionally, with demonstration of robust tetrodotoxin-sensitive and voltage-activated inward currents. Application of carbamazepine or phenytoin resulted in significant inhibition of current amplitude for carbamazepine (31.6 +/- 5.9%, n = 9; p < 0.001), and for phenytoin (35.5 +/- 6.9%, n = 7; p < 0.001). SIGNIFICANCE: Mouse osteoblasts express NaV , and native NaV currents are blocked by carbamazepine and phenytoin, supporting our hypothesis that AEDs can directly influence osteoblast function and potentially affect bone strength.
Effect of phenytoin on sodium conductances in rat hippocampal CA1 pyramidal neurons.[Pubmed:27489371]
J Neurophysiol. 2016 Oct 1;116(4):1924-1936.
The antiepileptic drug phenytoin (PHT) is thought to reduce the excitability of neural tissue by stabilizing sodium channels (NaV) in inactivated states. It has been suggested the fast-inactivated state (IF) is the main target, although slow inactivation (IS) has also been implicated. Other studies on local anesthetics with similar effects on sodium channels have implicated the NaV voltage sensor interactions. In this study, we reexamined the effect of PHT in both equilibrium and dynamic transitions between fast and slower forms of inactivation in rat hippocampal CA1 pyramidal neurons. The effects of PHT were observed on fast and slow inactivation processes, as well as on another identified "intermediate" inactivation process. The effect of enzymatic removal of IF was also studied, as well as effects on the residual persistent sodium current (INaP). A computational model based on a gating charge interaction was derived that reproduced a range of PHT effects on NaV equilibrium and state transitions. No effect of PHT on IF was observed; rather, PHT appeared to facilitate the occupancy of other closed states, either through enhancement of slow inactivation or through formation of analogous drug-bound states. The overall significance of these observations is that our data are inconsistent with the commonly held view that the archetypal NaV channel inhibitor PHT stabilizes fast inactivation states, and we demonstrate that conventional slow activation "IS" and the more recently identified intermediate-duration inactivation process "II" are the primary functional targets of PHT. In addition, we show that the traditional explanatory frameworks based on the "modulated receptor hypothesis" can be substituted by simple, physiologically plausible interactions with voltage sensors. Additionally, INaP was not preferentially inhibited compared with peak INa at short latencies (50 ms) by PHT.